Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Infection and Drug Resistance|June 24, 2026
Effect of Early Administration of Casirivimab and Imdevimab in Hospitalized Patients with COVID-19: A Post Hoc AnalysisEleftherios Mylonakis, Amy Sullivan, Selin Somersan-Karakaya, et al.
Journal of Visualized Experiments : Jove|January 7, 2017
Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of MycobacteriaBen Gold, Julia Roberts, Yan Ling, et al.
ACS Infectious Diseases|March 28, 2019
Nitrooxidoreductase Rv2466c-Dependent Fluorescent Probe for Mycobacterium tuberculosis Diagnosis and Drug Susceptibility TestingRan Mu, Chengcheng Kong, Wenjun Yu, et al.
Antimicrobial Agents and Chemotherapy|August 5, 2015
Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosisBen Gold, Julia Roberts, Yan Ling, et al.
BMJ Open|January 17, 2024
Thematic analysis to explore patients' experiences with long COVID-19: a conceptual model of symptoms and impacts on daily livesDiana Rofail, Selin Somersan-Karakaya, Julia Y Choi, et al.
Journal of Medicinal Chemistry|April 4, 2014
Synthetic calanolides with bactericidal activity against replicating and nonreplicating Mycobacterium tuberculosisPurong Zheng, Selin Somersan-Karakaya, Shichao Lu, et al.
Journal of Patient-Reported Outcomes|August 8, 2024
The symptoms evolution of long COVID‑19 (SE-LC19): a new patient-reported content valid instrumentDiana Rofail, Selin Somersan-Karakaya, Eleftherios Mylonakis, et al.
European Journal of Medicinal Chemistry|February 22, 2014
Benzimidazole-based compounds kill Mycobacterium tuberculosisYaling Gong, Selin Somersan Karakaya, Xiaoyong Guo, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 2017
Rifamycin action on RNA polymerase in antibiotic-tolerant <i>Mycobacterium tuberculosis</i> results in differentially detectable populationsKohta Saito, Thulasi Warrier, Selin Somersan-Karakaya, et al.
Mbio|October 18, 2022
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing AntibodiesAndrea T Hooper, Selin Somersan-Karakaya, Shane E McCarthy, et al.
Pageof 3